A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression

  title={A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression},
  author={Peter Nagele and Ben Julian A Palanca and Britt M. Gott and Frank Brown and Linda Barnes and Thomas Nguyen and Willa Xiong and Naji C Salloum and Gemma D. Espejo and Christina N. Lessov-Schlaggar and Nisha Jain and Wayland W. L. Cheng and Helga Komen and Branden Yee and Jacob D. Bolzenius and Alvin Janski and Robert Gibbons and Charles F. Zorumski and Charles R. Conway},
  journal={Science Translational Medicine},
Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration. Laughing gas improves depression About one-third of individuals suffering from depression are at risk for treatment resistance. Whereas inhaled 50% nitrous oxide has early antidepressant effects on individuals with treatment-resistant major depression (TRMD), adverse effects can occur at this concentration. In this phase 2 clinical trial… 
Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry
Introduction There is an imminent need for faster-acting and more effective antidepressants beyond the monoaminergic hypothesis. Methods We systematically searched the US Clinical Trials registry for
Physiological basis underlying antidepressant-induced activation of TrkB receptors
The results suggest that the phenomenon underlying TrkB transactivation—changes in energy expenditure and thermoregulation—is essential, but not sufficient, for antidepressant responses, regardless of differential clinical and pharmacodynamic properties.
Nitrous oxide for the treatment of psychiatric disorders: A systematic review of the clinical trial landscape
To systematically review published research studies and ongoing clinical trials investigating nitrous oxide (N2O) in psychiatric disorders, providing an up‐to‐date snapshot of the clinical research
Perspective Chapter - NMDA Treatments for CNS Disorders
The current strategy of N MDAR modulation for CNS disorders are elaborated on to discern underlying neurophysiological mechanisms of how homeostatic regulation of NMDAR plays a vital role in the normal and pathological states, respectively.
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Understanding similarities and differences in brain ICNs features underlying treatment response will positively impact the trajectory and outcomes for adults suffering from MDD and will facilitate the development of biomarkers to enable glutamate-based precision therapeutics.


Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Prolonged Remission of Major Depressive Disorder After Single Nitrous Oxide Inhalation Treatment
A case where a patient with severe recurrent treatment resistant major depression experienced full remission, which lasted more than 1 month, after a single nitrous oxide inhalation treatment is presented.
Effect of Nitrous Oxide as a Treatment for Subjective, Idiopathic, Nonpulsatile Bothersome Tinnitus: A Randomized Clinical Trial
Nitrous oxide was no more effective than placebo for the treatment of subjective, idiopathic tinnitus and the difference between the placebo and nitrous oxide arms was neither clinically meaningful nor statistically significant.
Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts.
The goal of this brief review was to educate psychiatrists about the basic concepts of nitrous oxide administration and pharmacology.
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients, and the results do not support previous findings that antidepressants show little benefit except for severe depression.
Prevalence of treatment-resistant depression in primary care: cross-sectional data.
  • L. Thomas, D. Kessler, N. Wiles
  • Medicine, Psychology
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 2013
The high prevalence of treatment-resistant depression in UK primary care is an important challenge facing clinicians, and a more proactive approach to managing this patient population is required to improve outcome.
European Society of Anaesthesiology Task Force on Nitrous Oxide: a narrative review of its role in clinical practice
Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
This is the first research synthesis of suicidal thoughts and behavior in depressed patients treated with antidepressants that examined the mediating role of depressive symptoms using complete longitudinal person-level data from a large set of published and unpublished studies.
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
It is shown that N2O, at anesthetically-relevant concentrations, inhibits both ionic currents and excitotoxic neurodegeneration mediated through NMDA receptors and, like other NMDA antagonists, produces neurotoxic side effects which can be prevented by drugs that enhance CABAergic inhibition.